t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs

被引：0
|
作者：
T Narita
A Inagaki
T Kobayashi
Y Kuroda
T Fukushima
M Nezu
S Fuchida
H Sakai
N Sekiguchi
I Sugiura
Y Maeda
H Takamatsu
N Tsukamoto
D Maruyama
Y Kubota
M Kojima
K Sunami
T Ono
M Ri
K Tobinai
S Iida
机构：
[1] Nagoya City University Graduate School of Medical Sciences,Department of Hematology and Oncology
[2] Nagoya City West Medical Center,Department of Hematology and Oncology
[3] Kyoto Prefectural University of Medicine,Division of Hematology and Oncology, Department of Medicine
[4] Research Center for Radiation Casualty Medicine,Department of Hematology and Oncology
[5] Research Institute for Radiation Biology and Medicine,Department of Hematology and Immunology
[6] Hiroshima University,Department of Hematology
[7] Kanazawa Medical University,Department of Hematology
[8] National Cancer Center Hospital East,Division of Hematology and Oncology, Department of Internal Medicine
[9] Kyoto Kuramaguchi Medical Center,Division of Hematology
[10] St Marianna University School of Medicine,Division of Hematology and Oncology
[11] National Hospital Organization Disaster Medical Center,Department of Hematology and Oncology
[12] Toyohashi Municipal Hospital,Department of Hematology
[13] Okayama University,Division of Hematology, Department of Internal Medicine
[14] Cellular Transplantation Biology,Division of Hematology/Oncology, Department of Internal medicine
[15] Kanazawa University Graduate School of Medical Sciences,Department of Hematology
[16] Oncology Center,Department of Internal Medicine III
[17] Gunma University Hospital,undefined
[18] National Cancer Center Hospital,undefined
[19] Respiratory Medicine and Oncology,undefined
[20] Faculty of Medicine,undefined
[21] Saga University,undefined
[22] Tokai University School of Medicine,undefined
[23] National Hospital Organization Okayama Medical Center,undefined
[24] Hamamatsu University School of Medicine,undefined
来源：
Blood Cancer Journal | 2015年 / 5卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：e285 / e285
相关论文
共 17 条
  • [1] t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs
    Narita, T.
    Inagaki, A.
    Kobayashi, T.
    Kuroda, Y.
    Fukushima, T.
    Nezu, M.
    Fuchida, S.
    Sakai, H.
    Sekiguchi, N.
    Sugiura, I.
    Maeda, Y.
    Takamatsu, H.
    Tsukamoto, N.
    Maruyama, D.
    Kubota, Y.
    Kojima, M.
    Sunami, K.
    Ono, T.
    Ri, M.
    Tobinai, K.
    Iida, S.
    BLOOD CANCER JOURNAL, 2015, 5 : e285 - e285
  • [2] Chromosomal Translocation (14;16)-Positive Multiple Myeloma Shows Negativity for CD56 Expression and Unfavorable Outcome Even in the Era of Novel Drugs
    Narita, Tomoko
    Inagaki, Atsushi
    Kobayashi, Tsutomu
    Kuroda, Yoshiaki
    Fukushima, Toshihiro
    Nezu, Masahiko
    Fuchida, Shin-ichi
    Sakai, Hirotaka
    Sekiguchi, Naohiro
    Sugiura, Isamu
    Maeda, Yoshinobu
    Takamatsu, Hiroyuki
    Tsukamoto, Norifumi
    Maruyama, Dai
    Kubota, Yasushi
    Kojima, Minoru
    Sunami, Kazutaka
    Ono, Takaaki
    Ri, Masaki
    Tobinai, Kensei
    Iida, Shinsuke
    BLOOD, 2014, 124 (21)
  • [3] Dual Negativity of CD56 and CD117 Links to Unfavorable Cytogenetic Abnormalities and Predicts Poor Prognosis in Multiple Myeloma
    Zheng, Dong
    Zhu, Mingxia
    Li, Qihui
    Wan, Wenli
    Chen, Yingtong
    Jing, Hongmei
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (21)
  • [4] CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction
    Skerget, Matevz
    Skopec, Barbara
    Zadnik, Vesna
    Zontar, Darja
    Podgornik, Helena
    Rebersek, Katarina
    Furlan, Tadej
    Cernelc, Peter
    ACTA HAEMATOLOGICA, 2018, 139 (04) : 228 - 234
  • [5] CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome
    Koumpis, Epameinondas
    Tassi, Iliana
    Malea, Theodora
    Papathanasiou, Konstantina
    Papakonstantinou, Ioannis
    Serpanou, Anastasia
    Tsolas, Evangelos
    Kapsali, Eleni
    Vassilakopoulos, Theodoros P.
    Papoudou-Bai, Alexandra
    Hatzimichael, Eleftheria
    PATHOLOGY RESEARCH AND PRACTICE, 2021, 225
  • [6] The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era
    Okura, Miyuki
    Ida, Naoko
    Yamauchi, Takahiro
    MEDICAL ONCOLOGY, 2020, 37 (11)
  • [7] The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era
    Miyuki Okura
    Naoko Ida
    Takahiro Yamauchi
    Medical Oncology, 2020, 37
  • [8] A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report
    Gozzetti, Alessandro
    Cerase, Alfonso
    Crupi, Rosaria
    Raspadori, Donatella
    Defina, Marzia
    Bocchia, Monica
    Lauria, Francesco
    LEUKEMIA RESEARCH, 2011, 35 (11) : E206 - E208
  • [9] Is t(11;14) in newly diagnosed multiple myeloma a favorable outcome in the novel agent era?
    Li, Ye
    Deng, Jingjing
    Jian, Yuan
    Zhang, Zhiyao
    Chen, Wenming
    BLOOD RESEARCH, 2025, 60 (01)
  • [10] T(11;14), Cyclin D1, CD20 and CD56 in Multiple Myeloma: A Retrospective Study of Pathologic and Clinical Associations
    Szabo, Agoston Gyula
    Gang, Anne Ortved
    Poulsen, Tim Svenstrup
    Klausen, Tobias Wirenfeldt
    Norgaard, Peter H.
    BLOOD, 2012, 120 (21)
12